Related Experiment Video
Updated: Jan 10, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Therapeutic effects of Ilicifolius acid a in murine ulcerative colitis
Yina Zhao1, Zhizhong Zheng2, Zile Shao2
1Fisheries College of Jimei University, Xiamen, China.
Ethnopharmacological Relevance:
The pathogenesis of ulcerative colitis (UC) is characterized by inflammatory responses and significant impairment of intestinal barrier function. The compromised integrity of the intestinal barrier leads to increased permeability, allowing gut microbiota to translocate across the epithelial layer and activate immune cells, thereby exacerbating inflammatory reactions. Acanthus ilicifolius L., a mangrove plant native to tropical and subtropical intertidal zones between 30°N and 30°S latitudes, has been traditionally used in Chinese folk medicine. Recognized for its therapeutic properties, this medicinal herb exhibits detoxifying, anti-inflammatory, and anti-tumor effects, with various extracts demonstrating significant pharmacological activities, including inflammation suppression and tumor inhibition.
Aim Of The Study:
In this study, we investigated the therapeutic potential of Ilicifolius acid A (IaA), a tannin compound derived from Acanthus ilicifolius L., in alleviating ulcerative colitis (UC) in mice. Notably, this work focused on evaluating the bioactivity of IaA rather than its extraction or isolation.
Materials And Methods:
A mouse model of ulcerative colitis was successfully established through administration of dextran sulfate sodium(DSS), and the potential therapeutic effects of IaA were systematically evaluated using quantitative PCR, Western blot analysis, and comprehensive omics sequencing approaches.
Results:
The administration of IaA significantly alleviates dextran sulfate sodium (DSS)-induced colitis symptoms, including weight loss, colon shortening, and splenomegaly. Further investigations demonstrate that IaA treatment effectively reduces inflammatory responses in colonic tissues and promotes repair of DSS-induced intestinal barrier damage. 16S rRNA sequencing analysis reveals a notable increase in the Alpha diversity index following IaA intervention. Proteomic sequencing results indicate that IaA exerts its therapeutic effects through suppression of the MAPK/Akt signaling pathway activation.
Conclusions:
IaA demonstrates a significant role in mitigating inflammation and promoting the repair of the intestinal barrier in murine models of ulcerative colitis, indicating its potential as a promising therapeutic candidate for the treatment of ulcerative colitis.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Constipation-Predominant IBS